New paper on our Max-directed chemical probe is out in Cell Chemical Biology!

We are very excited to finally share in long-form the story of KI-MS2-008, a Max-directed small molecule probe that attenuates Myc-driven transcription, which is now available for download at Cell Chemical Biology!

This work has been a highly collaborative team effort—originating in the work of many Koehler lab alumni and affiliates; greatly enhanced by the contributions of collaborators at Stanford University, Baylor College of Medicine, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute; and championed by lead authors Nick Struntz and Andrew Chen. We are grateful to the team and extend congratulations to all!

Graphical abstract from our most recent publication on KI-MS2-008 in Cell Chemical Biology.

Graphical abstract from our most recent publication on KI-MS2-008 in Cell Chemical Biology.

For a non-technical description of this project and its impact, please see our feature on MIT News.

For the short form specifications on the chemical probe and its discovery, please see our new pages for KI-MS2-008 and Max on our probe and target pages, respectively.

To request access to the compound, please visit our contact page.
The compound is not currently available from commercial sources; however, we intend to make the probe available to any colleagues unable to synthesize the molecule who wish to leverage the molecule for their own studies.

Kronos Bio opens shop at Lab Central!

In order to translate the work our group has been pursuing over the past decade into the clinic, the Koehler Lab is excited to share that late last year Dr. Koehler co-founded the company Kronos Bio


Kronos, through a partnership with Two River, has assembled a top-notch launch team and secured an excellent space in LabCentral, the shared laboratory for biotech innovation space down the street from our group at the Koch Institute. Under the recently announced leadership of Dr. Norbert Bischofberger, the Kronos team will be leveraging the small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.